To compare days to diagnosis of pregnancy location for same-day medication abortion and same-day uterine aspiration with delayed treatment (expectant management) in patients with undesired pregnancy of unknown location (PUL).
We conducted a retrospective cohort study at a single Planned Parenthood health center in Minnesota. We reviewed electronic health records and included patients presenting for induced abortion diagnosed with PUL (positive high-sensitivity urine pregnancy test and no evidence of intrauterine or extrauterine pregnancy on transvaginal ultrasonography) without symptoms or ultrasonographic imaging concerning for ectopic pregnancy (low risk). The primary outcome was days to pregnancy location clinical diagnosis.
Of 19,151 abortion encounters in 2016–2019, 501 (2.6%) had a low-risk PUL. Participants chose delay-for-diagnosis before treatment (148, 29.5%), immediate treatment medication abortion (244, 48.7%), or immediate treatment uterine aspiration (109, 21.8%). Median days to diagnosis were significantly lower in the immediate treatment uterine aspiration group (2 days, IQR 1–3 days, p < 0.001) and similar for immediate treatment medication abortion (4 days, IQR 3–9 days, p = 0.304) compared with delay-for-diagnosis (3 days, IQR 2–10 days). Thirty-three low-risk participants (6.6%) were treated for ectopic pregnancy, but no difference in ectopic rate was detected among groups (p = 0.725). Participants in the delay-for-diagnosis group were more likely to be nonadherent with follow-up (p < 0.001). For participants who completed follow-up, abortion completion rate was lower for immediate treatment medication abortion (85.2%) compared with immediate treatment uterine aspiration (97.6%, p = 0.003).
For patients with undesired PUL, diagnosis of pregnancy location was fastest with immediate treatment uterine aspiration and similar for expectant management and immediate treatment medication abortion. Medication abortion efficacy may be reduced in treatment of undesired PUL.
For PUL patients desiring induced abortion, the option of proceeding at initial encounter may help improve access and patient satisfaction. Uterine aspiration for PUL may help diagnose pregnancy location more quickly.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Contraception
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Prioritizing desiredness in pregnancy of unknown location: an algorithm for patient-centered care.Obstet Gynecol. 2020; 136: 1001-1005https://doi.org/10.1097/AOG.0000000000004124
- Guideline No. 414: management of pregnancy of unknown location and tubal and nontubal ectopic pregnancies.J Obstet Gynaecol Can. 2021; 43: 614-630.e1https://doi.org/10.1016/j.jogc.2021.01.002
Guttmacher, State bans on abortion throughout pregnancy 13 Aug 2022.
- Mifepristone and misoprostol for undesired pregnancy of unknown location.Obstet Gynecol. 2022; 139: 771-780https://doi.org/10.1097/AOG.0000000000004756
- Expectant management of early pregnancies of unknown location: a prospective evaluation of methods to predict spontaneous resolution of pregnancy.BJOG Int J Obstet Gynaecol. 2001; 108: 158-163https://doi.org/10.1111/j.1471-0528.2001.00031.x
- Efficacy of medical abortion prior to 6 gestational weeks: a systematic review.Contraception. 2018; 97: 90-99https://doi.org/10.1016/j.contraception.2017.09.006
- Surgical abortion prior to 7 weeks of gestation.Contraception. 2013; 88: 7-17https://doi.org/10.1016/j.contraception.2013.02.008
- Effectiveness of early medical abortion using low-dose mifepristone and buccal misoprostol in women with no defined intrauterine gestational sac.Contraception. 2013; 87: 855-858https://doi.org/10.1016/j.contraception.2012.10.013
- Mifepristone and misoprostol for early abortion when no gestational sac is present.Contraception. 2001; 63: 251-254https://doi.org/10.1016/s0010-7824(01)00200-1
- Efficacy and safety of very early medical termination of pregnancy: a cohort study.BJOG. 2017; 124: 1993-1999https://doi.org/10.1111/1471-0528.14904
- Outpatient endometrial aspiration: an alternative to methotrexate for pregnancy of unknown location.Am J Obstet Gynecol. 2017; 217: 185.e1-185.e9https://doi.org/10.1016/j.ajog.2017.04.023
- Change in quantitative human chorionic gonadotropin after manual vacuum aspiration in women with pregnancy of unknown location.Am J Obstet Gynecol. 2009; 200: e56-e59https://doi.org/10.1016/j.ajog.2008.10.013
- New technologies permit safe abortion at less than six weeks’ gestation and provide timely detection of ectopic gestation.Am J Obstet Gynecol. 1997; 176: 1101-1106https://doi.org/10.1016/s0002-9378(97)70410-1
- Manual compared with electric vacuum aspiration for abortion at less than 6 weeks of gestation.Obstet Gynecol. 2015; 125: 1121-1129https://doi.org/10.1097/AOG.0000000000000787
- Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial.Obstet Gynecol. 2008; 112: 1303-1310https://doi.org/10.1097/AOG.0b013e31818d8eb4
Published online: February 15, 2023
Accepted: February 10, 2023
Received in revised form: January 26, 2023
Received: November 5, 2022
Publication stageIn Press Corrected Proof
☆Conflicts of interest: None of the authors have any related conflicts of interest.
☆☆Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
© 2023 Elsevier Inc. All rights reserved.